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Abstract
Background: Statins possess immunomodulatory properties and have been proposed for reducing morbidity during an
influenza pandemic. We sought to evaluate the effect of statins on hospitalizations and deaths related to seasonal influenza
outbreaks.
Methodology/Principal Findings: We conducted a population-based cohort study over 10 influenza seasons (1996 to 2006)
using linked administrative databases in Ontario, Canada. We identified all adults older than 65 years who had received an
influenza vaccination prior to the start of influenza season and distinguished those also prescribed statins (23%) from those
not also prescribed statins (77%). Propensity-based matching, which accounted for each individual’s likelihood of receiving
a statin, yielded a final cohort of 2,240,638 patients, exactly half of whom received statins. Statins were associated with small
protective effects against pneumonia hospitalization (odds ratio [OR] 0.92; 95% CI 0.89–0.95), 30-day pneumonia mortality
(0.84; 95% CI 0.77–0.91), and all-cause mortality (0.87; 95% CI 0.84–0.89). These protective effects attenuated substantially
after multivariate adjustment and when we excluded multiple observations for each individual, declined over time, differed
across propensity score quintiles and risk groups, and were unchanged during post-influenza season periods. The main
limitations of this study were the observational study design, the non-specific outcomes, and the lack of information on
medications while hospitalized.
Conclusions/Significance: Statin use is associated with a statistically significant but minimal protective effect against
influenza morbidity that can easily be attributed to residual confounding. Public health officials and clinicians should focus
on other measures to reduce morbidity and mortality from the next influenza pandemic.
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Introduction
Influenza causes an estimated 1 million worldwide deaths
annually[1] and a future influenza pandemic as severe as the 1918-
20 pandemic would cause about 62 million deaths.[2] Some
strains of avian influenza have a case fatality rate of around
60%.[3] The ultimate impact of the current influenza A(H1N1)
pandemic remains uncertain. Availability of a vaccine against the
pandemic strain is largely restricted to a select group of countries
with manufacturers. The utility of non-vaccine antiviral medica-
tions is similarly hampered by limited production capacity and
viral resistance. The strategy of public health measures (e.g., social
distancing and face masks) is of uncertain effectiveness.
Recommendations for inexpensive generic medications that
target the host immune response to mitigate the effects of influenza
are a topic of broad interest.[4] Several studies have demonstrated
excessive elevations in pro-inflammatory cytokines and chemokines
associated with severe influenza infections.[5–8] Statins, therefore,
have real potential due to their ability to reduce levels of pro-
inflammatory cytokines and increase levels of anti-inflammatory
cytokines.[9–17] Treatment with statins has been shown in some
non-randomized studies to be associated withdecreased progression
to severe sepsis and reduced mortality from sepsis.[18–20] Previous
studies examining the benefits of statins on pneumonia morbidity
and mortality, however, have found conflicting results with some
showing large protective effects[21–26] and others finding no
protection.[27,28]
The prospect of using statins to combat an influenza pandemic
is enticing because they are widely available, have a long shelf-life,
and will not induce viral resistance. Clinicians also have extensive
familiarity with their pharmacologic profile. However, if statins are
actually ineffective their widespread use could potentially cause
more harm than good due to adverse drug reactions such as
hepatitis and myositis. Therefore, accurately estimating the
effectiveness of statins in preventing serious influenza-related
outcomes is a priority for global public health. The purpose of this
PLoS ONE | www.plosone.org 1 November 2009 | Volume 4 | Issue 11 | e8087study was to evaluate the effect of statins on hospitalizations and
deaths related to influenza.
Methods
Setting and Patients
We assembled a retrospective cohort of patients by linking
multiple administrative health-care databases over a ten year
period (1996 to 2006) in the province of Ontario, Canada’s most
populous province. The population included 12.2 million as of
2006, including 1.6 million people aged 65 or older. All elderly
patients had free access to hospital care, physician services, and
prescription medications. Ethics approval was obtained from the
Sunnybrook Health Sciences Centre Research Ethics Board,
Toronto, Canada.
The study period included ten influenza seasons (1996–97 to
2005–06). We used respiratory virus surveillance data from a
network of sentinel laboratories to identify influenza season
periods, in accord with previous research.[29] We identified the
start and end of influenza seasons as the first and last occurrences
of at least two consecutive weeks during which the weekly
percentage of tests positive for influenza was 5% or greater. We
chose this more inclusive definition for influenza season to increase
event counts (different intervals tested in sensitivity analyses).
We used several large, validated databases for this study. The
Ontario Drug Benefits (ODB) database recorded all prescription
medications dispensed to elderly patients.[30,31] The Canadian
Institute for Health Information (CIHI) Discharge Abstract
database recorded detailed information about diagnoses and
procedures for all hospitalizations.[32] The Ontario Health
Insurance Plan (OHIP) database recorded physician billing claims
for inpatient and outpatient services for 98% of Ontario
physicians.[33] The Ontario Registered Persons Database (RPDB)
recorded the vital status of all individuals in the province.[34]
Encrypted unique identifiers allowed for linkage of individuals
across all databases.
We included all patients older than 65 years who received an
influenza vaccination, measured using physician billing claims at
least 2 weeks prior to the start of an influenza season in OHIP
(G538/G539 during October and November or G590/G591 at
any time).[35] These codes have a specificity of 90% and a positive
predictive value of 96% for influenza vaccination. [35] The small
number of false positive codes reflects individuals who may have
received non-influenza vaccines. The study period included ten
separate influenza seasons; hence, each patient could be included
in the cohort a maximum of ten times (different models tested in
sensitivity analyses).
Patients were characterized as statin users if they received one
or more prescriptions for a statin during the 90 days preceding the
start of an influenza season (index date). The six statins available
during the study period were atorvastatin, cerivastatin, fluvastatin,
lovastatin, pravastatin, and simvastatin. Individuals who did not
receive a statin prescription during this 3-month period were
characterized as controls.
The primary study outcome was hospitalization for pneumonia
(ICD9-CM codes 480–487 and ICD10-CA codes J10-J18) during
influenza season. Secondary outcomes were deaths from any cause
within 30 days following such an admission and deaths from all
causes during influenza season.
We obtained individual data on more than 100 demographic
factors, previous health care use, specific procedures, current
prescription medications, and risk factors for influenza (Table S1)
from multiple datasets.[36,37] Risk factors for influenza were
defined as listed in the Canadian Immunization Guide indica-
tions.[38] Comorbidities were defined based on an adaptation of
the adjusted clinical group as any mention of the diagnosis in the
outpatient or hospitalization datasets during the prior three
years[39].
For each statin user, we identified one control who did not
receive a statin using propensity-based matching.[40] To do so, we
first calculated propensity scores for statin treatment in each
patient-year in the cohort based on an extensive list of factors
potentially related to statin use or influenza (Table S1).[38] We
next matched each statin user to a smaller pool of controls by sex,
age (plus or minus one year), and influenza season. Ultimately, we
selected in a 1:1 fashion the control with the closest propensity
score (within 0.2 SD) to each statin user. We discarded any
unmatched statin users and unmatched controls.
Statistical Analyses
We used conditional logistic regression models to estimate the
risk of an outcome during influenza season periods in statin users
compared to controls for the entire cohort and for each influenza
season separately. We also performed adjusted analyses that
controlled for the following pre-specified covariates: age, sex,
chronic institutionalization, number of hospitalizations in the prior
three years, number of medications prescribed in the prior year,
and risk factors for influenza-related complications (ischemic heart
disease, congestive heart failure, chronic obstructive pulmonary
disease, diabetes mellitus with complications, serious cancers,
chronic renal failure, and dementia and delirium).
Sensitivity Analyses
We conducted multiple sensitivity analyses to test the robustness
of our findings. We repeated the analysis without propensity score
matching and instead used standard multivariate regression
methods. We also repeated the analysis using a more restrictive
definition for influenza season periods that included only the five
consecutive weeks of greatest influenza activity.[29] To eliminate
potential bias arising from including individuals repeatedly over
multiple influenza seasons, we performed an analysis that included
only the first appearance of each individual. To check the effect of
statins on outcomes when influenza was not circulating in the
community, we also repeated the analyses for the post-influenza
season (defined as June 1 to September 30 each year), using the 90
days prior to the start of the post-influenza season to characterize
statin use. To assess the specificity of the association between statin
use and the main study outcomes, we replicated the analysis using
negative tracer outcomes for which no associations were expected:
hospitalizations for pericarditis (ICD-9-CM codes 391.0, 393, 420,
423.1-423.2 and ICD-10-CA codes I01.0, I09.2, I30, I31.0-I31.1,
I32) and for motor vehicle collisions (ICD-9-CM codes E810-E825
and ICD-10-CA codes V01-V79).
We conducted several subgroup analyses by dividing the cohort
based on: sex; age (less than versus greater than or equal to the
median age); hospitalizations in the past three years (none versus
any); the number of current medications prescribed (fewer than
versus greater than or equal to nine); the presence of any of the
influenza-related risk factors listed in Table 1 (none versus any);
and the type of statin prescribed (atorvastatin, simvastatin,
pravastatin, and other statins). To examine the effect of statins
across likelihood of receiving statins, we divided the cohort into
quintiles based on the propensity score and repeated the analysis
for each outcome.
Analyses were performed using SAS 9.1 (SAS Institute Inc.,
Cary, NC). All tests were two-tailed and we used p,0.05 as the
level of statistical significance.
Pandemic Influenza Implication
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The percentage of elderly individuals in Ontario who received
at least one prescription for a statin during a given year increased
steadily over the study period, from 8.6% in 1996 to 40.0% in
2006 (Figure 1). We identified 1,565,074 statin users and
5,112,221 controls over the ten year study interval. Characteristics
of the cohort before and after matching are presented in Table S1.
After matching, 1,120,319 pairs of statin users and non-users
remained in the cohort. The two matched groups appeared very
similar (Table 1). There were 13,027 pneumonia hospitalizations,
2,205 deaths within 30 days of such an admission, and 17,472
deaths from all causes over the ten influenza seasons.
In the primary analysis, statin use showed a small but
statistically significant apparent protective association against
hospitalization (OR=0.92; 95% CI 0.89–0.95) (Table 2). This
apparent effect was reduced substantially in the adjusted analysis
(0.97; 95% CI 0.94–1.00). When examining the effect by influenza
season, statins appeared to be protective during six seasons (1996–
97 to 2001–02) but not during four seasons (2002–03 to 2005–06)
(Figure 2).
The apparent protective association with statins was slightly
larger against 30-day pneumonia mortality (0.84; 95% CI 0.77–
0.91) and all-cause mortality (0.87; 95% CI 0.84–0.89) (Table 2).
These estimates also shifted towards the null after multivariate
adjustment. For all-cause mortality but not for 30-day pneumonia
mortality, the year-specific analyses displayed similar temporal
inconsistencies as observed for hospitalizations (Figure 2).
Without propensity score matching, statin use was associated
with apparent protection against all three outcomes in the crude
analysis that attenuated toward the null with adjustment (Table 2).
Using a more restrictive definition of influenza season yielded
similar results. Limiting the analysis to include only the first
appearance of an individual during the study period also shifted
the estimates towards the null, particularly for 30-day pneumonia
mortality. Associations calculated for the post-influenza season
analyses were either similar to or more pronounced than those
during influenza peaks. As anticipated, no association was
detected between statin use and hospitalizations for pericarditis
(1.05; 95% CI 0.78–1.42) or motor vehicle collisions (1.00; 95%
CI 0.83–1.21).
In the subgroup analyses, women obtained no protection from
statin use, whereas men showed a small trend (Figure 3).
Differences between older and younger individuals were minimal.
In contrast, dividing the cohort by recent hospitalizations, number
of prescription medications, and presence of risk factors for
influenza dramatically influenced the effect of statins, with statins
appearing protective for healthier individuals and harmful for
sicker individuals. When the analyses were repeated with the
cohort divided into quintiles based on the propensity score,
individuals in quintile 1 (i.e., those least likely to receive statins)
experienced no protection from statins against any outcome (1.00;
95% CI 0.93–1.07 for pneumonia hospitalization; 0.94; 95% CI
0.80–1.09 for 30-day pneumonia mortality; and 0.99; 95% CI
0.94–1.05 for all-cause mortality) (Table 2).
Discussion
We found a small, statistically significant apparent protective
association of statins against influenza morbidity and mortality.
However the association was inconsistent and could be easily
attributed to hidden confounding. The potential protective
association was not consistent over the study period or across
subgroups based on health status, propensity score, or when we
excluded multiple observations for each individual. Moreover, the
finding was not distinct to outcomes observed during influenza
seasons, although it is possible that any protective effect of statins,
if present, might not be specific to pneumonia resulting from
influenza infection. Together, these findings cast doubt on the role
of statins for treating an influenza pandemic.
The protection estimated in this study is much smaller than in
previous reports. For instance, van de Garde et al. and Schlienger et
al. reported 50% and 37% protection against pneumonia
hospitalization, respectively.[22,23] The comparable estimate
from our analysis is 8% (3% after adjustment). For 30-day
pneumonia mortality, previous estimates ranged from 31% to
64%, whereas our study showed 16% protection (10% after
adjustment).[21,23–26] The reduced benefits may indicate better
control of confounding due to more finely stratified disease
groupings. The use of such a small number of variables in those
studies was likely insufficient to account for most of the differences
between statin users and non-users.
Table 1. Baseline characteristics in the matched cohort.
Statin group Control group
(n=1,120,319) (n=1,120,319)
Demographic factors
Age (mean - years) (SD) 74.34 (5.78) 74.34 (5.78)
Sex (male) 505,264 (45.1%) 505,264 (45.1%)
Institutional care status 11,614 (1.0%) 9,971 (0.9%)
Health-care use
Number of admissions (past 3 years) 0.58 (1.19) 0.57 (1.16)
Number of medications (past year) 9.91 (5.72) 9.94 (6.73)
Risk factors for influenza
Ischemic heart disease + AMI 465,573 (41.6%) 462,182 (41.3%)
Congestive heart failure 122,505 (10.9%) 120,252 (10.7%)
Emphysema, chronic bronchitis, COPD 129,026 (11.5%) 128,667 (11.5%)
DM with complications 22,940 (2.0%) 22,915 (2.0%)
Serious cancers 40,295 (3.6%) 40,622 (3.6%)
Chronic renal failure 39,851 (3.6%) 39,304 (3.5%)
Dementia and delirium 49,574 (4.4%) 48,216 (4.3%)
AMI=acute myocardial infarction. COPD=chronic obstructive pulmonary
disease.
doi:10.1371/journal.pone.0008087.t001
Figure 1. Prevalence of statin use. Percentage of elderly population
who received at least one prescription for a statin each year over the
study period.
doi:10.1371/journal.pone.0008087.g001
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residual confounding, sometimes referred to as the ‘‘healthy user’’
effect, persists. Some patients who tend to engage in health-seeking
behaviours are more adherent to medical advice and are
sometimes ironically misclassified in administrative databases as
having greater numbers of coexisting conditions as other
patients.[27,28,41] The presence of the healthy user effect is
congruent with the change in protection from statins observed
over time in this study (since many new therapies are initially more
likely to be adopted by healthy users, and then followed by gradual
dissemination to sicker individuals).[42] Therefore, the spurious
benefits of statins will appear to decline over time. Further
evidence is the lack of benefit observed in the analysis that
included individuals only once. Healthy users tend to seek
Figure 2. Year-specific analyses. Odd ratios for statin use and pneumonia hospitalization (A), 30-day pneumonia mortality (B), and all-cause
mortality (C), by influenza season, with patients not treated with statins as the reference group. Horizontal lines show 95% CI.
doi:10.1371/journal.pone.0008087.g002
Table 2. Statins and influenza morbidity.
Odds ratio (95% CI)
Pneumonia hospitalization 30-day pneumonia mortality All-cause mortality
With propensity score matching – crude 0.92 (0.89–0.95) 0.84 (0.77–0.91) 0.87 (0.84–0.89)
With propensity score matching – adjusted 0.97 (0.94–1.00) 0.90 (0.82–0.98) 0.91 (0.88–0.94)
Without propensity score matching – crude 0.72 (0.71–0.74) 0.50 (0.47–0.53) 0.56 (0.55–0.57)
Without propensity score matching – adjusted 0.96 (0.93–0.99) 0.89 (0.83–0.95) 0.90 (0.88–0.92)
Restrict to peak influenza weeks – crude 0.89 (0.85–0.94) 0.79 (0.70–0.91) 0.86 (0.82–0.90)
Restrict to peak influenza weeks – adjusted 0.95 (0.90–1.00) 0.86 (0.75–0.98) 0.91 (0.86–0.95)
Limit to first appearance of individual – crude 0.94 (0.89–0.99) 0.97 (0.84–1.11) 0.92 (0.88–0.97)
Limit to first appearance of individual - adjusted 0.98 (0.93–1.04) 1.01 (0.88–1.17) 0.95 (0.90–1.00)
Change to post-influenza season – crude 0.93 (0.90–0.96) 0.81 (0.74–0.89) 0.79 (0.76–0.81)
Change to post-influenza season – adjusted 0.97 (0.93–1.00) 0.85 (0.78–0.92) 0.80 (0.78–0.82)
By propensity score quintile
Quintile 1 (least likely to be on a statin) 1.00 (0.93–1.07) 0.94 (0.80–1.09) 0.99 (0.94–1.05)
Quintile 2 0.86 (0.80–0.93) 0.73 (0.60–0.89) 0.86 (0.81–0.92)
Quintile 3 0.90 (0.83–0.97) 0.84 (0.69–1.02) 0.83 (0.78–0.89)
Quintile 4 0.90 (0.83–0.98) 0.88 (0.72–1.09) 0.81 (0.76–0.87)
Quintile 5 (most likely to be on a statin) 0.92 (0.85–0.99) 0.78 (0.64–0.96) 0.81 (0.75–0.87)
doi:10.1371/journal.pone.0008087.t002
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included in the analysis repeatedly; their presence in multiple years
would bias the estimates of protection.
This study had several limitations that merit emphasis. First, this
was an observational study, and we may not have been able to
entirely eliminate the effect of unmeasured confounders. Previous
work has demonstrated that propensity score methods are unable
to fully control for residual confounding.[43] Second, our
outcomes are non-specific and may have been due to causes
other than influenza. Third, we did not have information on
medications while hospitalized, although this was relevant only for
mortality outcomes. Finally, we used health administrative data for
assessing covariates with questionable accuracy of diagnostic
codes.
Among the strengths of this study, the most notable is its size.
With over 2.2 million person-years of observation resulting in
13,027 pneumonia hospitalizations during ten influenza seasons of
varying severity, our data form the largest study to date by a factor
of 75. We eliminated non-compliance with vaccination as a
confounder and examined actual treatment with statins in a
population-based community setting. Another strength is that we
used a large number of variables to develop the propensity score
model, with fine stratification of disease groupings. Lastly, we used
laboratory surveillance data to define influenza season periods.
Despite the exciting prospect suggested by previous studies, our
data suggest that statins do not substantially reduce morbidity and
mortality from influenza. Public health officials and clinicians
should focus on other measures to reduce morbidity and mortality
from the next influenza pandemic.
Supporting Information
Table S1 Cohort characteristics before and after matching.
Found at: doi:10.1371/journal.pone.0008087.s001 (0.22 MB
DOC)
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